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A B S T R A C T
Cardiotoxicity is an adverse effect of the anticancer drug doxorubicin (DOX). Gemfibrozil (GEM) is a lipid-
lowering drug with a number of biological properties such as anti-inflammatory and antioxidant activities.
Therefore, we decided to investigate the effect of GEM on DOX-induced cardiotoxicity in rats. Twenty-eight adult
male Wistar rats were divided into four experimental groups as follows: Group I received normal saline (2ml/kg)
orally for 14 days, group II received DOX (2.5mg/kg; in six injections; accumulative dose: 15mg/kg) in-
traperitonially for 14 days, group III received DOX+GEM (100mg/kg) orally for 14 days concomitantly with
DOX administration, and group IV received GEM orally for 14 days. Lipid panel, various biochemical bio-
markers, and histological observations were evaluated in serum and heart samples. According to our results,
DOX significantly increased the levels of lipid panel (triglycerides, total cholesterol, and low-density lipoproteins
cholesterol) as well as markers of cardiac dysfunction (Aspartate aminotransferase, Creatine kinase-muscle/
brain, Lactate dehydrogenase and Cardiac Troponin I). Moreover, DOX significantly increased malondialdehyde
and nitric oxide levels in cardiac tissue. Furthermore, administration of DOX reduced the level of glutathione as
well as the superoxide dismutase, catalase, and Glutathione peroxidase activities. DOX-treated rats showed
significantly higher tumor necrosis factor-α and interleukin-1β. GEM administration significantly attenuated the
lipid panel and biochemical biomarkers in DOX-treated rats. Our results were confirmed by histopathological
evaluations of the heart. Based on our findings, GEM is a promising cardioprotective agent in patients treated
with DOX through mitigative effects on biochemical markers and oxidative stress indices.
1. Introduction
The doxorubicin (DOX) is an anthracycline glycoside antibiotic and
an anticancer drug that cause DNA intercalation as well as inhibit the
DNA replication [1]. DOX has a wide spectrum of antineoplastic ac-
tivity such as breast cancer, leukemia, and sarcoma [2]. One of the most
common adverse effects of DOX is cardiotoxicity which is clinically
manifested as congestive heart failure [3]. Although the exact me-
chanisms underlying cardiac toxicity induced by DOX are not com-
pletely understood several reports confirmed that DOX increases the
inflammation and oxidative stress in the heart [4]. DOX induced-car-
diotoxicity is a limiting factor for using the maximum allowable dose of
DOX during anticancer treatment [5]. Therefore, using a compound or
drug alongside the DOX is helpful to attenuate the DOX-induced car-
diotoxicity [3]. It seems that antioxidant and anti-inflammatory com-
pounds or drugs such as resveratrol, quercetin and nicorandil have
protective effects on DOX-induced cardiotoxicity via preventing the
oxidative damage as well as increasing the antioxidant capacity and
reduced the inflammation processes [6–8].
Fibrates such as gemfibrozil (GEM) are agonists of peroxisome
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proliferator activated receptor- α (PPAR-α) which mainly reduce the
triglyceride levels of plasma [9]. GEM is among the most widely pre-
scribed drug for patients with hypertriglyceridemia and mixed dysli-
pidemia [10]. In addition to this well-established property, GEM exerts
a wide range of pharmacological properties such as antioxidant and
anti-inflammatory effects which may extend its clinical indications
[11,12]. It is well established that GEM inhibits the production and
releasing of inflammatory mediators including interleukin-1β (IL-1β)
and tumor necrosis factor-α (TNF-α) [11,13]. Also, it has shown that
GEM decreased oxidative stress and inflammation in a model of dia-
betes-associated atherosclerosis [12]. It was demonstrated that fenofi-
brate (other fibrates which also a PPAR-α activator) has a cardiopro-
tective effect in autoimmune myocarditis via reducing the
inflammation [14].
In the current context, we assessed the ability of GEM to prevent
cardiotoxicity induced by DOX, based on biochemical indices, oxidative
stress parameters, and pathological alterations.
2. Materials and methods
2.1. Animals
Twenty-eight healthy adult male Wistar rats (200 ± 10 g) were
used in this study. The rats were purchased from the animal house of
Ahvaz Jundishapur University of Medical Sciences. Animals were
housed with free access to water and food, a 12-h dark/light cycle (light
from 8:00 to 20:00) with the temperature kept constant at 22 ± 2 °C
[15]. The experimental procedures were conducted according to the
Animal Ethics Committee Guidelines for the use of experimental ani-
mals (Ethic code: IR.AJUMS.REC.1396.41).
2.2. Drugs and experimental design
DOX (EBEDOXO®) was obtained from EBEWE Company (Austria)
and GEM were purchased from Abidi Pharmaceutical Company (Iran).
After 2 weeks of acclimatization animals were aliquoted into four
groups (n= 7).
Group I received normal saline (NS; 2ml/kg) orally for 14 days.
Group II received DOX (2.5mg/kg) intraperitoneally (i.p.) in six
injections over a 2 weeks period (cumulative dose:15mg/kg) [6].
Group III received GEM (100mg/kg; orally) for 14 days con-
comitantly with DOX treatment (with the same dose in the aforemen-
tioned group) [16].
Group IV received GEM (with the same dose in the aforementioned
group).
2.3. Sample collection
One day after the last administration, the rats were anesthetized
with i.p. injection of ketamine (80mg/kg) and xylazine (8mg/kg).
Then, the blood samples were collected from the left ventricle. The
blood samples were centrifugated at 3000 rpm for 10min to separate
the serum and stored at −20 °C for lipid profile and biochemical ana-
lysis.
Then animals were decapitated, the heart tissues were isolated and
washed with ice-cold saline quickly. Each heart was divided into two
parts. One part was used for pathological study which fixed in 10%
phosphate-buffered formalin. The second part was used for other bio-
chemical study which minced and homogenized (1/10 w/v) with
Tris−HCl buffer (100mM, pH 7.4). Then, the homogenate was cen-
trifuged (6000 rpm, 20min, 4 °C) and the supernatant was collected and
stored at −80 °C.
2.4. Serum analyses
Lipid panel and markers of cardiac dysfunction were measured in
serum samples. Serum total cholesterol, triglycerides, high-density li-
poproteins cholesterol (HDL-c) and low-density lipoproteins cholesterol
(LDL-c) levels were determined by using a biochemical autoanalyzer
(MINDRAY, PR China) with respective test kits (Technicon, Bayer S.A.
Diagnostic). Aspartate aminotransferase (AST) activity was determined
by the Reitman and Frankel method [17]. Creatine kinase-muscle/brain
(CK-MB) activity was determined by the Bishop method [18]. Lactate
dehydrogenase (LDH) activity was determined by the Whitaker method
[19]. Cardiac Troponin I (cTnI) level was determined by an ELISA Kit
specific for rats, following the manufacturer’s protocol (MyBioSource,
USA; Catalog number: MBS727624).
2.5. Biochemical analyses
The antioxidant enzyme, markers of oxidative stress and in-
flammatory cytokines were measured in supernatant samples. The total
protein content was determined according to the method described by
Bradford [20].
The catalase (CAT) activity was estimated by the Aebi et al. method
[21]. The superoxide dismutase (SOD) activity was estimated by the
Martin et al. method [22]. The glutathione (GSH) content was esti-
mated by the Ellman et al. method [23]. Glutathione peroxidase (GPx)
activity was estimated by a glutathione peroxidase kit specific for rats,
according to the manufacturer’s protocol (ZellBio GmbH, Germany).
Cardiac lipid peroxidation was estimated by the Buege and Aust
method via measuring the malondialdehyde (MDA) levels [24]. Cardiac
nitric oxide (NO) level was estimated by the Griess assay [25].
The concentrations of TNF-α and IL-1β in the cardiac tissue
homogenate supernatant was measured by ELISA kit specific for rats,
according to the manufacturer’s protocol (IBL company; TNF-α catalog
number: 27,194 and IL-1β catalog number: 27,193).
2.6. Histopathological evaluations
The heart samples were embedded in paraffin, sectioned (thickness:
5 μm) and stained with hematoxylin and eosin dyes (H&E) for light
microscopic examinations. Six microscopy slides per animal were ex-
amined for assessment of histopathological changes such as nuclear
pyknosis, inflammatory cell infiltration, myocardial disorganization,
and myofibrillar loss.
2.7. Statistical analysis
GraphPad Prism software data analysis program version 6 was used
for statistical analysis (GraphPad Software, USA). Data were analyzed
by one-way analysis of variance (ANOVA) and presented as means ±
standard deviation (SD). Individual differences were determined by
Tukey’s post hoc test. A value of less than 0.05 was considered statis-
tically significant.
3. Results
3.1. Effects of DOX administration on serum, biochemical and
histopathological alternations in rats
In our study, DOX cardiotoxicity was confirmed in several aspects.
The DOX-treated rats showed significantly higher total cholesterol,
triglyceride, and LDL-c and significantly lower HDL-c compared to the
control group (p < 0.001 in all groups) (Table 1). The levels of cardiac
dysfunction markers such as AST, LDH, CKeMB, and cTnI were mark-
edly increased in the DOX-treated rats than their corresponding control
ones (p < 0.001 in all groups) (Fig. 1). The NO and MDA levels of the
heart were higher in the DOX group in comparison with the control
animals (p < 0.001 in all groups) (Fig. 2). Rats receiving DOX also
demonstrated a significant decrease in GSH level as well as the activity
of GPx, SOD, and CAT than control group (p < 0.001 in all groups)
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(Fig. 3). DOX group had higher pro-inflammatory cytokines (TNF-α and
IL-1β) contents in comparison with their control counterparts
(p < 0.001 in all groups) (Fig. 4). Moreover, pathological examination
revealed cardiomyocytes damage of DOX-treated rats such as myo-
cardial disorganization, loss of myofibrillar, red blood cells (RBCs)
congestion and infiltration of inflammatory cell (Fig. 5B).
3.2. Effects of GEM administration on serum, biochemical and
histopathological alternations in DOX-treated rats
Our results indicated that administration of GEM with DOX miti-
gated the cardiac damage of DOX. Administration of GEM significantly
reduced total cholesterol (p < 0.01), triglyceride (p < 0.001) and
LDL-c (p < 0.001) and significantly increased HDL-c (p < 0.05) in
comparison with the DOX group (Table 1). GEM attenuated the effect of
DOX administration on markers of cardiac dysfunction (AST, LDH,
CKeMB, and cTnI) (p < 0.05 for CKeMB; p < 0.01 for AST and cTnI;
p < 0.001 for LDH) which reflecting the amelioration of cardiotoxicity
in DOX-treated rats (Fig. 1). Moreover, GEM treatment (100mg/kg for
14 days) significantly reduced the MDA and NO levels in cardiac tissue
(p < 0.01 in all groups) (Fig. 2). Rats receiving GEM in combination
with DOX also demonstrated a significant increase in GSH content as
well as the activity of GPx than their corresponding control ones
(p < 0.01 in all groups) (Fig. 3). GEM attenuated the effect of DOX
treatment on inflammatory mediators (TNF-α and IL-1β) (p < 0.05 in
all groups) levels than their DOX counterparts (Fig. 4). We observed a
marked improvement in cardiac cells structure and nuclei as well as
normal cytoplasm structure in rats receiving of GEM (Fig. 5C).
3.3. Effects of GEM administration on serum, biochemical and
histopathological alternations in rats
GEM administration (100mg/kg for 14 days) did not induce any
serum, biochemical and histopathological changes in naïve rats com-
pared to their control counterparts.
4. Discussion
DOX, an effective anticancer drug, has life-threatening side effects
at a maximal therapeutic dose which may induce cardiac injury [2].
Table 1
Effect of gemfibrozil on lipid panel in doxorubicin-induced cardiotoxicity in rats.
NS DOX DOX+GEM GEM
Total cholesterol (mg/dL) 84.30 ± 6.30 146.6 ± 10.90*** 127.6 ± 9.40## 81.70 ± 5.50
Triglyceride (mg/dL) 95.23 ± 7.52 285.7 ± 18.45*** 173.6 ± 12.65### 84.12 ± 6.80
LDL-c (mg/dL) 17.53 ± 3.20 43.56 ± 5.95*** 30.10 ± 4.40### 15.75 ± 2.50
HDL-c (mg/dL) 38.12 ± 4.31 21.65 ± 3.94*** 29.10 ± 4.13# 43.55 ± 5.57
Values are mean ± SD (n= 7).
Data were analyzed by one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons.
*Significant change with respect to NS group (***p < 0.001).
#Significant change with respect to DOX group (#p < 0.05; ##p < 0.01 and ###p < 0.001).
Fig. 1. Effect of gemfibrozil on markers of
cardiac dysfunction in doxorubicin-induced
cardiotoxicity in rats. Values are means ± SD
(n=7). Data were analyzed by one-way
ANOVA followed by Tukey’s post hoc test for
multiple comparisons.
* Significant change with respect to NS group
(***p < 0.001).
# Significant change with respect to DOX
group (#p < 0.05; ##p < 0.01 and
###p < 0.001).
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The main points arising from the current study were that DOX-induced
inflammatory and oxidative injury in the cardiac tissue and GEM
treatment attenuated cardiotoxicity induced by DOX through its pro-
found antioxidant activity and anti-inflammatory properties.
It is well documented that DOX administration has deleterious ef-
fects on the lipid profile [5]. DOX-induced hyperlipidemia has dele-
terious effects for heart function and appears to contribute to DOX-in-
duced cardiotoxicity [26]. On the other hand, it is well established that
lipid-lowering drugs have protective effects against cardiotoxicity in-
duced by DOX [27]. In our study, the cardiac injury by six doses of DOX
(each dose: 2.5 mg/kg; cumulative dose: 15mg/kg) was associated with
significant increase in total cholesterol, triglyceride and LDL-c as well
as decrease in HDL-c while GEM caused to significantly improve in
these indies. Therefore, the cardioprotective effect of GEM in DOX-in-
duced cardiotoxicity may be mediated by its lipid-lowering property.
Increasing the serum levels of AST, LDH, CK-MB, and cTnI have
been indicated to cardiac tissue dysfunctions because these are nor-
mally located in the cytoplasm of cardiomyocytes and leakage occurs
into the serum after cardiomyocytes damage [28]. Administration of
DOX increases these cardiac markers in serum while co-administration
of GEM with DOX attenuated these disturbances. It is worth mentioning
that normalization serum levels of these markers by GEM indicating
protection of cardiac cells [8]. The most acceptable mechanism for
DOX-induced cardiotoxicity is oxidative stress [29]. These oxidative
stress cause damage to cell membranes and cellular macromolecules
such as lipids of the cardiomyocytes [1]. it is well established that GEM
possesses potent antioxidant activity though dependent and/or in-
dependent pathways to PPAR α receptors [30]. Nikravesh et al., showed
that GEM has protective effects against hepatotoxicity induced by
acetaminophen via reducing the ROS formation [31].
DOX-induced cardiac injury by the generation of ROS and the
protection of heart though augmentation of the cardiac antioxidant
Fig. 2. Effect of gemfibrozil on markers of
oxidative stress in doxorubicin-induced cardi-
otoxicity in rats. Values are means ± SD
(n=7). Data were analyzed by one-way
ANOVA followed by Tukey’s post hoc test for
multiple comparisons.
* Significant change with respect to NS group
(***p < 0.001).
# Significant change with respect to DOX
group (##p < 0.01).
Fig. 3. Effect of gemfibrozil on antioxidant
enzymes in doxorubicin-induced cardiotoxicity
in rats. Values are means ± SD (n= 7). Data
were analyzed by one-way ANOVA followed by
Tukey’s post hoc test for multiple comparisons.
* Significant change with respect to NS group
(***p < 0.001).
# Significant change with respect to DOX
group (##p < 0.01).
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defense system is critical in the protection against DOX-induced cardiac
damage [6,7,26]. On the other hand, previous studies indicating that
DOX administration is associated with reduction in enzymes involved in
antioxidant defense including SOD, CAT, GPx and GSH [3,8,26]. Our
results indicated that the activities of CAT, GPx and SOD as well as GSH
level significantly reduced in cardiac tissue of rats exposed to DOX. Our
results also showed that administration of GEM in combination with
DOX increased the activity of GPx and the content of GSH. Previous
studies showed that GEM increases the antioxidant capacity in different
conditions such as acetaminophen-induced hepatotoxicity and cis-
platin-induced nephrotoxicity [31,32]. Accordingly, it seems that GEM
may possibly show its cardioprotective effects by increasing the anti-
oxidant capacity.
DOX induces the production of NO and MDA in cardiac cells. These
markers of oxidative stress cause mitochondrial dysfunction that may
lead to organ damage [33,34]. On the other hand, GEM is known to
decrease the production of MDA and NO in different conditions such as
sepsis and diabetes [11,12]. Elevations in MDA and NO after DOX
Fig. 4. Effect of gemfibrozil on inflammatory
cytokines in doxorubicin-induced cardiotoxi-
city in rats. Values are means ± SD (n=7).
Data were analyzed by one-way ANOVA fol-
lowed by Tukey’s post hoc test for multiple
comparisons.
* Significant change with respect to NS group
(***p < 0.001).
# Significant change with respect to DOX
group (#p < 0.05).
Fig. 5. The effect of normal saline, doxorubicin, doxorubicin+ gemfibrozil and gemfibrozil administration on myocardium (stained with Hematoxylin & Eosin,
magnification X 150). (A) normal saline-treated rats showing normal morphological appearance; (B) doxorubicin-treated rats showing massive inflammation,
myofibrillar loss and congestion of red blood cells; (C) doxorubicin+ gemfibrozil treated rat showing mild inflammation and myofibrillar loss and (D) gemfibrozil-
treated rats showing normal morphological appearance.
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administration were observed in the current study. In addition, a sig-
nificant difference in the levels of MDA and NO were identified between
the DOX and DOX+GEM group. Thus, GEM might induce cardiopro-
tective effects through attenuation of DOX-induced oxidative injuries.
In addition to oxidative stress, the other mechanism that plays a
critical role in the pathogenesis of DOX-induced cardiotoxicity is in-
flammation [3]. It is well documented that the overproduction of free
radicals leads to increasing the production of inflammatory mediators
and trigger the inflammatory processes in the heart [26,35]. Moreover,
it is well established that GEM acts as an anti-inflammatory agent via
inhibition of inflammatory cytokine production and releases [13,36]. In
line with these previous reports, the results of our study demonstrated
that GEM administration alongside with DOX attenuated the TNF-α and
IL-1β levels in comparison with DOX-treated rats.
Marked oxidative stress results from DOX administration causes a
degenerative change in cardiac tissue which can lead to cardiomyocytes
damage such as necrosis [6]. GEM decreased the membrane peroxida-
tion and disruption of cardiac cells and subsequently attenuated ne-
crosis and tissue injuries. These findings are in line with the biochem-
ical assessments. The cardioprotective effects of GEM have been shown
only in heart transplantation. Benke et al., demonstrated that pre-
conditioning with GEM attenuates the ischemia/reperfusion injury as
well as preserves cardiac function after heart transplantation [37].
To conclude, our study showed that administration of GEM along-
side the DOX reduced the cardiac levels of NO, MDA, TNF-α, and IL-1β
as well as serum markers of cardiac injury such as AST, LDH, CK-MB,
and cTnI. We also found that GEM increase in GSH content, as well as
the activity of GPx in DOX-treated rats. These effects may explain the
amelioration of cardiac injury in DOX-induced cardiotoxicity through
improving the oxidative state and/or decreasing the inflammation.
More studies are required to elaborate the exact mechanism of GEM.
Finally, we suggest that further clinical trials with different lower doses
of GEM conducted to reveal the beneficial effects of GEM in the clinic.
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